Year 2017 / Volume 109 / Number 7
Original
Influence of type 2 diabetes mellitus on Khorana venous thromboembolism risk in colorectal cancer patients

503-509

DOI: 10.17235/reed.2017.4322/2016

Ruyao Wang, Rui Liu, Lijie Zhao, Dandan Xu, Liling Hu,

Abstract
Background: Many studies have documented the association between venous thromboembolism (VTE) and colorectal cancer (CRC). The Khorana model is a VTE risk assessment model for predicting cancer-associated thrombosis. Type 2 diabetes (T2DM) has also been reported to increase the risk of VTE. Purpose: The aim of this study was to investigate the influence of T2DM on Khorana VTE risk in CRC patients and to explore the relationship between Khorana VTE category and CRC clinicopathological factors. Methods: This analysis included 615 CRC patients (205 with T2DM). Fibrinogen and D-dimer levels were compared within each group. A comparison was made of the proportion of patients in different Khorana VTE risk categories in CRC patients with and without T2DM. The association between Khorana VTE risk category and clinicopathological factors among all the CRC patients was evaluated. Results: Fibrinogen levels of CRC patients with T2DM were significantly higher than those of non-diabetes patients (4.13 ± 1.06 vs 3.94 ± 0.98, p < 0.001). A higher proportion of CRC patients with T2DM were in the Khorana intermediate-to-high risk category (H = 4.749, p = 0.029). Female sex, diabetes, colon location (compared with rectum), larger tumor size, advanced pT stage and pN stage were correlated with the intermediate-to-high Khorana VTE risk category, with odd ratios (95% confidence intervals [CI]) of 1.537 (1.064-2.220), 1.499 (1.027-2.186), 2.313 (1.588-3.370), 2.284 (1.542-3.383), 4.429 (2.088-9.396) and 1.822 (1.230-2.698), respectively. Conclusion: T2DM increases Khorana VTE risk in CRC patients. Female sex, diabetes, colon location, large tumor size and poor stage are associated with the intermediate-to-high Khorana VTE risk category.
Share Button
New comment
Comments
No comments for this article
References
[1] Deng A., Galanis T. and Graham M. G.Venous thromboembolism in cancer patients[J].Hosp Pract (1995),2014,5:-24-33.
[2] Gary T.Cancer related venous thromboembolism - prophylaxis and therapy[J].Vasa,2014,4:-245-251.
[3] Piccioli A., Lensing A. W., Prins M. H., et al.Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial[J].J Thromb Haemost,2004,6:-884-889.
[4] Davenport D. L., Vargas H. D., Kasten M. W., et al.Timing and perioperative risk factors for in-hospital and post-discharge venous thromboembolism after colorectal cancer resection[J].Clin Appl Thromb Hemost,2012,6:-569-575.
[5] Alcalay A., Wun T., Khatri V., et al.Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival[J].J Clin Oncol,2006,7:-1112-1118.
[6] Khorana A. A., Francis C. W., Culakova E., et al.Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy[J].J Thromb Haemost,2007,3:-632-634.
[7] Lyman G. H.Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis[J].Cancer,2011,7:-1334-1349.
[8] Lutsey P. L., Virnig B. A., Durham S. B., et al.Correlates and consequences of venous thromboembolism: The Iowa Women's Health Study[J].Am J Public Health,2010,8:-1506-1513.
[9] Stein P. D., Goldman J., Matta F., et al.Diabetes mellitus and risk of venous thromboembolism[J].Am J Med Sci,2009,4:-259-264.
[10] Morel O., Jesel L., Abbas M., et al.Prothrombotic changes in diabetes mellitus[J].Semin Thromb Hemost,2013,5:-477-488.
[11] Osende J. I., Badimon J. J., Fuster V., et al.Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control[J].J Am Coll Cardiol,2001,5:-1307-1312.
[12] Fujiwara Y., Tagami S. and Kawakami Y.Circulating thrombomodulin and hematological alterations in type 2 diabetic patients with retinopathy[J].J Atheroscler Thromb,1998,1:-21-28.
[13] Khorana A. A., Kuderer N. M., Culakova E., et al.Development and validation of a predictive model for chemotherapy-associated thrombosis[J].Blood,2008,10:-4902-4907.
[14] Mandala M., Falanga A., Roila F., et al.Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management[J].Ann Oncol,2010,v274-276.
[15] Falanga A., Russo L. and Verzeroli C.Mechanisms of thrombosis in cancer[J].Thrombosis Research,2013,S59-S62.
[16] Nagy Z., Horvath O., Kadas J., et al.D-dimer as a potential prognostic marker[J].Pathol Oncol Res,2012,3:-669-674.
[17] Seebacher V., Polterauer S., Grimm C., et al.The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial[J].Br J Cancer,2010,6:-952-956.
[18] Coussens L. M. and Werb Z.Inflammation and cancer[J].Nature,2002,6917:-860-867.
[19] Sahni A., Simpson-Haidaris P. J., Sahni S. K., et al.Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2)[J].J Thromb Haemost,2008,1:-176-183.
[20] Kilic L., Yildiz I., Sen F. K., et al.D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients[J].Cancer Biomark,2015,
[21] Bai J., Ding X., Du X., et al.Diabetes is associated with increased risk of venous thromboembolism: a systematic review and meta-analysis[J].Thromb Res,2015,1:-90-95.
[22] Bell E. J., Folsom A. R., Lutsey P. L., et al.Diabetes mellitus and venous thromboembolism: A systematic review and meta-analysis[J].Diabetes Res Clin Pract,2016,10-18.
[23] Kim H. K., Kim J. E., Park S. H., et al.High coagulation factor levels and low protein C levels contribute to enhanced thrombin generation in patients with diabetes who do not have macrovascular complications[J].J Diabetes Complications,2014,3:-365-369.
[24] Jax T. W., Peters A. J., Plehn G., et al.Hemostatic risk factors in patients with coronary artery disease and type 2 diabetes - a two year follow-up of 243 patients[J].Cardiovasc Diabetol,2009,48.
[25] Sommeijer D. W., Hansen H. R., van Oerle R., et al.Soluble tissue factor is a candidate marker for progression of microvascular disease in patients with Type 2 diabetes[J].J Thromb Haemost,2006,3:-574-580.
[26] Khechai F., Ollivier V., Bridey F., et al.Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes. Role of oxidant stress and protein tyrosine kinase activation[J].Arterioscler Thromb Vasc Biol,1997,11:-2885-2890.
[27] Lu Y., Zhou Z. Y., Liu Y. K., et al.Gender differences of venous thromboembolism risk after total hip and total knee arthroplasty: a meta-analysis[J].J Thromb Thrombolysis,2015,
[28] Sasaki K., Kawai K., Tsuno N. H., et al.Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer[J].World J Surg,2012,1:-192-200.
[29] Ahlbrecht J., Dickmann B., Ay C., et al.Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study[J].J Clin Oncol,2012,31:-3870-3875.
Related articles

Letter

Vaginal lesion as first manifestation of colorectal disease

DOI: 10.17235/reed.2022.9270/2022

Review

Inflammatory bowel disease and solid organ transplantation

DOI: 10.17235/reed.2020.7361/2020

Review

New non-invasive biomarkers for colorectal cancer screening

DOI: 10.17235/reed.2020.7233/2020

Letter

Medullary colorectal carcinoma. Do we really know it?

DOI: 10.17235/reed.2020.6728/2019

Letter

The rectosigmoid junction: are limits important?

DOI: 10.17235/reed.2019.5983/2018

Editorial

Colorectal cancer screening and survival

DOI: 10.17235/reed.2018.5870/2018

Letter to the Editor

Liver metastasis from colorectal cancer 12 years after liver transplantation

DOI: 10.17235/reed.2017.4507/2016

Review

Serrated lesions and serrated polyposis syndrome

DOI: 10.17235/reed.2017.4065/2015

Letter to the Editor

Endobronchial metastases of colorectal cancer

DOI: 10.17235/reed.2016.4080/2015

Citation tools
Wang R, Liu R, Zhao L, Xu D, Hu L. Influence of type 2 diabetes mellitus on Khorana venous thromboembolism risk in colorectal cancer patients. 4322/2016


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 96 visits.
This article has been downloaded 96 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 13/03/2016

Accepted: 09/03/2017

Online First: 08/06/2017

Published: 30/06/2017

Article revision time: 356 days

Article Online First time: 452 days

Article editing time: 474 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology